Hikma Pharmaceuticals PLC HIK shares inched up 0.88% to £19.53 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Health is an independent 501(c)(3) nonprofit making digital health systems and is not affiliated with Hikma Pharmaceuticals PLC or any of its affiliates.

We read every piece of feedback, and take your input very seriously.